Podcasts about global burden

In this episode, Lyell K. Jones Jr, MD, FAAN, speaks with Michael S. Okun, MD, FAAN, who served as the guest editor of the August 2025 Movement Disorders issue. They provide a preview of the issue, which publishes on August 1, 2025. Dr. Jones is the editor-in-chief of Continuum: Lifelong Learning in Neurology® and is a professor of neurology at Mayo Clinic in Rochester, Minnesota. Dr. Okun is the director at Norman Fixel Institute for Neurological Diseases and distinguished professor of neurology at University of Florida in Gainesville, Florida. Additional Resources Read the issue: continuum.aan.com Subscribe to Continuum®: shop.lww.com/Continuum Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @LyellJ Guest: @MichaelOkun Full episode transcript available here: Dr Jones: Our ability to move through the world is one of the essential functions of our nervous system. Gross movements like walking ranging down to fine movements with our eyes and our hands, our ability to create and coordinate movement is something many of us take for granted. So what do we do when those movements stop working as we intend? Today I have the opportunity to speak with one of the world's leading experts on movement disorders, Dr Michael Okun, about the latest issue of Continuum on Movement Disorders. Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about subscribing to the journal, listening to verbatim recordings of the articles, and exclusive access to interviews not featured on the podcast. Dr Jones: This is Dr Lyle Jones, Editor-in-Chief of Continuum: Lifelong Learning in Neurology. Today, I'm interviewing Dr Michael Okun, who is Continuum's guest editor for our latest issue on movement disorders. Dr Okun is the Adelaide Lackner Distinguished Professor of Neurology at the University of Florida in Gainesville, where he's also the director of the Norman Fixel Institute for Neurological Diseases. Dr Okun, welcome, and thank you for joining us today. Why don't you introduce yourselves to our listeners?  Dr Okun: It's great to be here today. And I'm a neurologist. Everybody who knows me knows I'm pretty simple. I believe the patient's the sun and we should always orbit around the person with disease, and so that's how I look at my practice. And I know we always participate in a lot of research, and I've got a research lab and all those things. But to me, it's always the patients and the families first. So, it'll be great to have that discussion today.  Dr Jones: Yeah, thank you for that, Dr Oaken. Obviously, movement disorders is a huge part of our field of neurology. There are many highly prevalent conditions that fit into this category that most of our listeners will be familiar with: idiopathic Parkinson's disease, essential tremor, tic disorders and so on. And having worked with trainees for a long time, it's one of the areas that I see a lot of trainees gravitate to movement disorders. And I think it's in part because of the prevalence; I think it's in part because of the diversity of the specialty with treatment options and DBS and Botox. But it's also the centrality of the neurologic exam, right? That's- the clinical examination of the patient is so fundamental. And we'll cover a lot of topics today with some questions that I have for you about biomarkers and new developments in the field. But is that your sense too, that people are drawn to just the old-fashioned, essential focus on the neurologic encounter and the neurologic exam? Dr Okun: I believe that is one of the draws to the field of movement. I think that you have neurologists from all over the world that are really interested and fascinated with what things look like. And when you see something that's a little bit, you know, off the normal road or off the normal beaten path… and we are always curious. And so, I got into movement disorders, I think, accidentally; I think even as a child, I was looking at people who had abnormal movements and tremors and I was very fascinated as to why those things happened and what's going on in the brain. And, you know, what are the symptoms and the signs. And then later on, even as my own career developed, that black bag was so great as a neurologist. I mean, it makes us so much more powerful than any of the other clinicians---at least in my biased opinion---out on the wards and out in the clinic. And, you know, knowing the signs and the symptoms, knowing how to do a neurological examination and really walking through the phenomenology, what people look like, you know, which is different than the geno- you know, the genotypes, what the genes are. What people look like is so much more important as clinicians. And so, I think that movement disorders is just the specialty for that, at least in my opinion. Dr Jones: And it helps bring it back to the patient. And that's something that I saw coming through the articles in this issue. And let's get right to it. You've had a chance to review all these articles on all these different topics across the entire field of movement disorders. As you look at that survey of the field, Dr Okun, what do you think is the most exciting recent development for patients with movement disorders?  Dr Okun: I think that when you look across all of the different specialties, what you're seeing is a shift. And the shift is that, you know, a lot of people used to talk in our generation about neurology being one of these “diagnose and adios” specialties. You make the diagnosis and there's nothing that you can do, you know, about these diseases. And boy, that has changed. I mean, we have really blown it out of the water. And when you look at the topics and what people are writing about now and the Continuum issue, and we compare that the last several Continuum issues on movement disorders, we just keep accumulating a knowledge base about what these things look like and how we can treat them. And when we start thinking about, you know, all of the emergence of the autoimmune disorders and identifying the right one and getting something that's quite treatable. Back in my day, and in your day, Lyle, we saw these things and we didn't know what they were. And now we have antibodies, now we can identify them, we can pin them down, and we can treat many of them and really change people's lives. And so, I'm really impressed at what I see in changes in identification of autoimmune disorders, of channelopathies and some of the more rare things, but I'm also impressed with just the fundamental principles of how we're teaching people to be better clinicians in diseases like Parkinson's, Huntington's, ataxia, and Tourette. And so, my enthusiasm for this issue of Continuum is both on, you know, the cutting edge of what we're seeing based on the identification on our exams, what we can do for these people, but also the emergence of how we're shifting and providing much better care across a continuum for folks with basal ganglia diseases. Dr Jones: Yeah, I appreciate that perspective, Dr Okun. One of the common themes that I saw in the issue was with these new developments, right, when you have new tools like new diagnostic biomarker tools, is the question of if and when and how to integrate those into daily clinical practice, right? So, we've had imaging biomarkers for a while, DAT scans, etc. For patients with idiopathic Parkinson disease, one of the things that I hear a lot of discussion and controversy about are the seed amplification assays as diagnostic biomarkers. What can you tell us about those? Are those ready for routine clinical use yet?  Dr Okun: I think the main bottom-line point for folks that are out there trying to practice neurology, either in general clinics or even in specialty clinics, is to know that there is this movement toward, can we biologically classify a disease? One of the things that has, you know, really accelerated that effort has been the development of these seed amplification assays, which---in short for people who are listening---are basically, we “shake and bake” these things. You know? We shake them for like 20 hours and we use these prionlike proteins, and we learn from diseases like prion disease how to kind of tag these things and then see, do they have degenerative properties? And in the case of Parkinson's disease, we're able to do this with synuclein. That is the idea of a seed amplification assay. We're able to use this to see, hey, is there synuclein present or not in this sample? And people are looking at things like cerebrospinal fluid, they're looking at things like blood and saliva, and they're finding it. The challenge here is that, remember- and one of the things that's great about this issue of Continuum is, remember, there are a whole bunch of different synucleinopathies. So, Dr Jones, it isn't just Parkinson's disease. So, you've got Parkinson's disease, you've got Lewy body, you know, and dementia with Lewy bodies. You've got, you know, multiple system atrophy is within that synucleinopathy, you know, group primary autonomic failure… so not just Parkinson's disease. And so, I think we have to tap the brakes as clinicians and just say, we are where we are. We are moving in that direction. And remember that a seed amplification assay gives you some information, but it doesn't give you all the information. It doesn't forgive you looking at a person over time, examining them in your clinic, seeing how they progress, seeing their response to dopamine- and by the way, several of these genes that are associated with Parkinson; and there's, you know, less than 20% of Parkinson is genetic, but several of these genes, in a solid third---and in some cases, in some series, even more---miss the synuclein assay, misses, you know, the presence of a disease like Parkinson's disease. And so, we have to be careful in how we interpret it. And I think we're more likely to see over time a gemish: we're going to smush together all this information. We're going to get better with MRIs. And so, we're actually doing much better with MRIs and AI-based intelligence. We've got DAT scans, we've got synuclein assays. But more than anything, everybody listening out there, you can still examine the person and examine them over time and see how they do over time and see how they do with dopamine. And that is still a really, really solid way to do this. The synuclein assays are probably going to be ready for prime time more in choosing and enriching clinical trials populations first. And you know, we're probably 5, 10 years behind where Alzheimer's is right now. So, we'll get there at some point, but it's not going to be a silver bullet. I think we're looking at these are going to be things that are going to be interpreted in the context for a clinician of our examination and in the context of where the field is and what you're trying to use the information for. Dr Jones: Thank you for that. And I think that's the general gestalt I got from the articles and what I hear from my colleagues. And I think we've seen this in other domains of neurology, right? We have the specificity and sensitivity issues with the biomarkers, but we also have the high prevalence of copathology, right? People can have multiple different neurodegenerative problems, and I think it gets back to that clinical context, like you said, following the patient longitudinally. That was a theme that came out in the idiopathic Parkinson disease article. And while we're on Parkinson disease, you know, the first description of that was what, more than two hundred years ago. And I think we're still thinking about the pathophysiology of that disorder. We understand risk factors, and I think many of our listeners would be familiar with those. But as far as the actual cause, you know, there's been discussion in recent years about, is there a role of the gut microbiome? Is this a prionopathic disorder? What's your take on all of that?  Dr Okun: Yeah, so it's a great question. It's a super-hot area right now of Parkinson. And I kind of take this, you know, apart in a couple of different ways. First of all, when we think about Parkinson disease, we have to think upstream. Like, what are the cause and causes? Okay? So, Parkinson is not one disease, okay? And even within the genes, there's a bunch of different genes that cause it. But then we have to look and say, well, if that's less than 20% depending on who's counting, then 80% don't have a single piece of DNA that's closely associated with this syndrome. And so, what are we missing with environment and other factors? We need to understand not what happens at the end of the process, not necessarily when synuclein is clumping- and by the way, there's a lot of synuclein in the brains normally, and there's a lot of Tau in people's brains who have Parkinson as well. We don't know what we don't know, Dr Jones. And so when we begin to think about this disease, we've got to look upstream. We've got to start to think, where do things really start? Okay? We've got to stop looking at it as probably a single disease or disorder, and it's a circuit disorder. And then as we begin to develop and follow people along that pathway and continuum, we're going to realize that it's not a one-size-fits-all equation when we're trying to look at Parkinson. By the way, for people listening, we only spend two to three cents out of every dollar on prevention. Wouldn't prevention be the best cure, right? Like, if we were thinking about this disease. And so that's something that we should be, you know, thinking about. And then the other is the Global Burden of Disease study. You know, when we wrote about this in a book called Ending Parkinson's Disease, it looked like Parkinson's was going to double by 2035. The new numbers tell us it's almost double to the level that we expected in 2035 in this last series of numbers. So, it's actually growing much faster. We have to ask why? Why is it growing faster? And then we have lots of folks, and even within these issues here within Continuum, people are beginning to talk about maybe these environmental things that might be blind spots. Is it starting in our nose? Is it starting in our gut? And then we get to the gut question. And the gut question is, if we look at the microbiomes of people with Parkinson, there does seem to be, in a group of folks with Parkinson, a Parkinson microbiome. Not in everyone, but if you look at it in composite, there seems to be some clues there. We see changes in Lactobacillus, we see some bacteria going up that are good, some bacteria going down, you know, that are bad. And we see flipping around, and that can change as we put people on probiotics and we try to do fecal microbiota transplantations- which, by the way, the data so far has not been positive in Parkinson's. Doesn't mean we might not get there at some point, but I think the main point here is that as we move into the AI generation, there are just millions and millions and millions of organisms within your gut. And it's going to take more than just our eyes and just our regular arithmetic. You and I probably know how to do arithmetic really well, but this is, like, going to be a much bigger problem for computers that are way smarter than our brains to start to look and say, well, we see the bacteria is up here. That's a good bacteria, that's a good thing or it's down with this bacteria or this phage or there's a relationship or proportion that's changing. And so, we're not quite there. And so, I always tell people---and you know, we talk about the sum in the issue---microbiomes aren't quite ready for prime time yet. And so be careful, because you could tweak the system and you might actually end up worse than before you started. So, we don't know what we don't know on this issue.  Dr Jones: And that's a great point. And one of the themes they're reading between the lines is, we will continue to work on understanding the bio-pathophysiology, but we can't wait until that day to start managing the risk factors and treating patients, which I think is a good point. And if we pivot to treatment here a little bit, you know, one of the exciting areas of movement disorders---and really neurology broadly, I think movement disorders has led the field in many ways---is bioelectronic therapy, or what one of my colleagues taught me is “electroceutical therapy”, which I think is a wonderful term. Dr Okun, when our listeners are hearing about the latest in deep brain stimulation in patients who have movement disorders, what should they know? What are the latest developments in that area with devices? Dr Okun: Yeah. So, they should know that things are moving rapidly in the field of putting electricity into the brain. And we're way past the era where we thought putting a little bit of electricity was snake oil. We know we can actually drive these circuits, and we know that many of these disorders---and actually, probably all of the disorders within this issue of Continuum---are all circuit disorders. And so, you can drive the circuit by modulating the circuit. And it's turned out to be quite robust with therapies like deep brain stimulation. Now, we're seeing uses of deep brain stimulation across multiple of these disorders now. So, for example, you may think of it in Parkinson's disease, but now we're also seeing people use it to help in cases where you need to palliate very severe and bothersome chorea and Huntington's disease, we're seeing it move along in Tourette syndrome. We of course have seen this for various hyperkinetic disorders and dystonias. And so, the main thing for clinicians to realize when dealing with neuromodulation is, take a deep breath because it can be overwhelming. We have a lot of different devices in the marketplace and no matter how many different devices we have in the marketplace, the most important thing is that we get the leads. You know, where we're stimulating into the right location. It's like real estate: location, location, location, whether you've got a lead that can steer left, right, up, down and do all of these things. Second, if you're feeling overwhelmed because there are so many devices and so many settings, especially as we put these leads in and they have all sorts of different, you know, nodes on them and you can steer this way and that way, you are not alone. Everybody is feeling that way now. And we're beginning to see AI solutions to that that are going to merge together with imaging, and then we're moving toward an era of, you know, should I say things like robotic programming, where it's going to be actually so complicated as we move forward that we're going to have to automate these systems. There's no way to get this and scale this for all of the locales within the United States, but within the entire world of people that need these types of devices and these therapies. And so, it's moving rapidly. It's overwhelming. The most important thing is choosing the right person. Okay? For this, with multidisciplinary teams, getting the lead in the right place. And then all these other little bells and whistles, they're like sculpting. So, if you think of a sculpture, you kind of get that sculpture almost there. You know, those little adds are helping to maybe make the eyes come out a little more or the facial expression a little bit better. There's little bits of sculpting. But if you're feeling overwhelmed by it, everybody is. And then also remember that we're starting to move towards some trials here that are in their early stages. And a lot of times when we start, we need more failures to get to our successes. So, we're seeing trials of people looking at, like, oligo therapies and protein therapies. We're seeing CRISPR gene therapies in the laboratory. And we should have a zero tolerance for errors with CRISPR, okay? we still have issues with CRISPR in the laboratory and which ones we apply it to and with animals. But it's still pretty exciting when we're starting to see some of these therapies move forward. We're going to see gene therapies, and then the other thing we're going to see are nano-therapies. And remember, smaller can be better. It can slip across the blood brain barrier, you have very good surface area-to-volume ratios, and we can uncage drugs by shining things like focused ultrasound beams or magnets or heat onto these particles to turn them on or off. And so, we're seeing a great change in the field there. And then also, I should mention: pumps are coming and they're here. We're getting pumps like we have for diabetes and neurology. It's very exciting. It's going to be overwhelming as everybody tries to learn how to do this. So again, if you're feeling overwhelmed, so am I. Okay? But you know, pumps underneath the skin for dopamine, pumps underneath the skin for apomorphine. And that may apply to other disorders and not just Parkinson as we move along, what we put into those therapies. So, we're seeing that age come forward. And then making lesions from outside the brain with focused ultrasound, we're starting to get better at that. Precision is less coming from outside the brain; complications are also less. And as we learn how to do that better, that also can provide more options for folks. So, a lot of things to read about in this issue of Continuum and a lot of really interesting and beyond, I would say, you know, the horizon as to where we're headed.  Dr Jones: Thank you for that. And it is a lot. It can be overwhelming, which I guess is maybe a good reason to read the issue, right? I think that's a great place to end and encourage our listeners to pick up the issue. And Dr Okun, I want to thank you for joining us today. Thank you for such a great discussion on movement disorders. I learned a lot. I'm sure our listeners will as well, given the importance of the topic, your leadership in the field over many years. I'm grateful that you have put this issue together. So, thank you. And you're a busy person. I don't know how we talked you into doing this, but I'm really glad that we did.  Dr Okun: Well, it's been my honor. And I just want to point out that the whole authorship panel that agreed to write these articles, they did all the work. I'm just a talking head here, you know, telling you what they did, but they're writing, and the people that are in the field are really, you know, leading and helping us to understand, and have really put it together in a way that's kind of helped us to be better clinicians and to impact more lives. So, I want to thank the group of authors, and thank you, Dr Jones. Dr Jones: Again, we've been speaking with Dr Michael Okun, guest editor of Continuum's most recent issue on movement disorders. Please check it out. And thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. Thank you for listening to Continuum Audio.

Die Themen in den Wissensnachrichten: +++ Wie sich politische Lager wieder näherkommen können +++ Warum Kinder weltweit schlechter vor Krankheiten geschützt sind +++ Wie Sauerteig für gesünderes Brot sorgt +++**********Weiterführende Quellen zu dieser Folge:Learning to Like the Enemy: Moral Learning Reduces Affective Polarization, Social Psychological and Personality Science, 18.06.2025Global, regional, and national trends in routine childhood vaccination coverage from 1980 to 2023 with forecasts to 2030: a systematic analysis for the Global Burden of Disease Study 2023, The Lancet, 24.06.2025Gefährdete Säugetiere: Populationen auf kleinen Inseln sind gesünder, LMU München, 25.06.2025The importance of small-island populations for the long-term survival of endangered large-bodied insular mammals, 24.06.2025Akustisches Frühwarnsystem für Brückenschäden, Fraunhofer IDMT, 18.06.2025Alle Quellen findet ihr hier.**********Ihr könnt uns auch auf diesen Kanälen folgen: TikTok und Instagram .

Le "paradoxe français" désigne une observation intrigante : les Français, malgré une alimentation riche en graisses saturées (fromages, beurre, charcuterie), ont un taux relativement bas de maladies cardiovasculaires, en comparaison avec d'autres pays occidentaux comme les États-Unis. Cette contradiction apparente a été mise sous les projecteurs aux États-Unis le 17 novembre 1991, lors d'un épisode de l'émission très populaire 60 Minutes diffusée sur CBS. Le segment, intitulé "The French Paradox", présentait l'idée que la consommation régulière de vin rouge par les Français pourrait être la clé de leur bonne santé cardiovasculaire.L'impact de cette émission a été immédiat : selon les données du Wine Market Council, les ventes de vin rouge ont augmenté de 44 % aux États-Unis dans les mois qui ont suivi. En 1992, le vin rouge représentait environ 70 % des nouvelles ventes de vin sur le marché américain, contre seulement 50 % l'année précédente. Certaines marques françaises comme Château Lafite Rothschild ont vu leur popularité exploser, et les importations de vin français ont fortement progressé.Sur le plan scientifique, l'un des principaux promoteurs de ce concept était le chercheur Serge Renaud de l'INSERM à Lyon. Dans un article publié en 1992 dans The Lancet, il avance que la consommation modérée de vin rouge – un à deux verres par jour – pourrait réduire le risque de maladies coronariennes de 40 %. Le vin rouge contient en effet des polyphénols, dont le plus connu est le resvératrol, un antioxydant présent dans la peau du raisin. Des études comme celle de J.P. Fremont (1999, Life Sciences) ont suggéré que le resvératrol inhibe l'agrégation des plaquettes et protège les vaisseaux sanguins.Le "paradoxe français" est alors devenu un argument marketing massif. L'industrie vinicole, en France comme aux États-Unis, s'en est emparée pour promouvoir le vin rouge comme un produit "santé". Cette stratégie a contribué à modifier l'image du vin outre-Atlantique, le faisant passer d'un produit de luxe européen à un choix de consommation perçu comme bénéfique.Cependant, cette idée a été nuancée fortement depuis. Aujourd'hui on sait que scientifiquement, la consommation modérée d'alcool n'est pas totalement sans risque, même à faibles doses.Citons l'étude de référence : The Lancet, 2018 – Global Burden of Disease StudyIl s'agit de l'une des études les plus vastes jamais réalisées sur le sujet, couvrant plus de 28 millions de personnes dans 195 pays. Elle conclut que le niveau de consommation d'alcool le plus sûr est zéro. Même à faibles doses, l'alcool augmente les risques de certains cancers, de maladies cardiovasculaires et de blessures.Cette étude remet donc totalement en cause l'idée selon laquelle une consommation modérée, comme un verre de vin par jour, pourrait être bénéfique pour la santé. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

For decades, the great fear was overpopulation. Now it's the opposite. How did this happen — and what's being done about it? (Part one of a three-part series, “Cradle to Grave.”) SOURCES:Matthias Doepke, professor of economics at the London School of Economics.Amy Froide, professor of history at the University of Maryland, Baltimore County.Diana Laird, professor of obstetrics and gynecology at the University of California, San Francisco.Catherine Pakaluk, professor of economics at The Catholic University of America. RESOURCES:"Fertility Rate, Total for the United States," (Federal Reserve Bank of St. Louis, 2025)."Global fertility in 204 countries and territories, 1950–2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021," (The Lancet, 2024)."Suddenly There Aren't Enough Babies. The Whole World Is Alarmed." by Greg Ip and Janet Adamy (The Wall Street Journal, 2024)."Taxing bachelors and proposing marriage lotteries – how superpowers addressed declining birthrates in the past," by Amy Froide (University of Maryland, 2021)."Is Fertility a Leading Economic Indicator?" by Kasey Buckles, Daniel Hungerman, and Steven Lugauer (National Bureau of Economic Research, 2018).The King's Midwife: A History and Mystery of Madame du Coudray, by Nina Rattner Gelbart (1999).The Population Bomb, by Paul Ehrlich (1970)."An Economic Analysis of Fertility," by Gary Becker (National Bureau of Economic Research, 1960). EXTRAS:"What Will Be the Consequences of the Latest Prenatal-Testing Technologies?" by Freakonomics Radio (2011).

Marie Ng speaks to Hui Wu about four Global Burden of Disease studies on cardiovascular diseases, smoking, mental health and injury in the ASEAN to inform public health priorities setting and policy planning.You can read the four GBD papers here:Smoking: https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(24)00326-8/fulltext?dgcid=buzzsprout_icw_podcast_May_25_lanpubInjury burden: https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(25)00069-6/fulltext?dgcid=buzzsprout_icw_podcast_May_25_lanpubCardiovascular disease: https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(25)00087-8/fulltext?dgcid=buzzsprout_icw_podcast_May_25_lanpubMental disorders: https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(25)00098-2/fulltext?dgcid=buzzsprout_icw_podcast_May_25_lanpubContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Drs Carol H. Wysham and Liana K. Billings discuss how to incorporate SGLT2 inhibitors and GLP-1 receptor agonists into the management of patients with type 2 diabetes and chronic kidney disease. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002049. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Type 2 Diabetes Mellitus https://emedicine.medscape.com/article/117853-overview Chronic Kidney Disease (CKD) https://emedicine.medscape.com/article/238798-overview Global, Regional, and National Burden of Chronic Kidney Disease Due to Diabetes Mellitus Type 2 From 1990 to 2021, With Projections to 2036: A Systematic Analysis for the Global Burden of Disease Study 2021 https://pubmed.ncbi.nlm.nih.gov/40034386/ Advantages, Limitations, and Clinical Considerations in Using Cystatin C to Estimate GFR https://pubmed.ncbi.nlm.nih.gov/36514729/ New Creatinine- and Cystatin C-Based Equations to Estimate GFR Without Race https://pubmed.ncbi.nlm.nih.gov/34554658/ Effects of Semaglutide on Chronic Kidney Disease in Patients With Type 2 Diabetes https://pubmed.ncbi.nlm.nih.gov/38785209/ Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy https://pubmed.ncbi.nlm.nih.gov/30990260/ Dapagliflozin in Patients With Chronic Kidney Disease https://pubmed.ncbi.nlm.nih.gov/32970396/ Empagliflozin in Patients With Chronic Kidney Disease https://pubmed.ncbi.nlm.nih.gov/36331190/ Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 https://pubmed.ncbi.nlm.nih.gov/39651975/ CKD Early Identification & Intervention Toolkit https://kdigo.org/wp-content/uploads/2019/01/ISN_KDIGO_EarlyScreeningBooklet_WEB_updatedOct11.pdf Combination Therapy as a New Standard of Care in Diabetic and Non-Diabetic Chronic Kidney Disease https://pubmed.ncbi.nlm.nih.gov/39907542/ Living With Chronic Kidney Disease and Type 2 Diabetes Mellitus: The Patient and Clinician Perspective https://pubmed.ncbi.nlm.nih.gov/36282450/

In this insightful conversation, Dr. Beau Beard sits down with Dr. Steven Capobianco—clinician, educator, and fascia researcher—to unpack the evolving landscape of manual therapy, pain science, and movement-based care.From the history of trigger points and Travell & Simons to modern fascia research from Stecco, they challenge outdated paradigms and offer a fresh framework for integrating touch, neuroscience, and patient-centered care.Topics include:- Why trigger points are still debated—and why they still matter- Fascia's role in pain and movement, beyond the hype- Rethinking touch: from mechanical to neurological- How to implement the biopsychosocial model with clarity and confidence- The rise in chronic pain—and what clinicians might be missingThis is not about pushing techniques—it's about elevating clinical reasoning. Whether you're a chiropractor, physio, trainer, or just fascinated by how the body works, this is a must-listen.***Chapters00:00 Introduction and Personal Updates05:18 Experiences at the Fix Congress08:40 Fascia and Its Importance in Manual Therapy10:34 The Bio-Psycho-Social Model in Treatment14:10 Historical Context of Manual Therapy22:50 The Evolution of Trigger Point Research32:37 The Controversy of Fascia and Manual Therapy35:36 Curiosity in Evidence-Based Practice39:03 The Complexity of Pain and Movement41:30 The Role of Touch in Therapy50:53 Centrally Mediated Pain and Trigger Points56:54 The Importance of Patient Expectations and Data Gathering01:07:28 Understanding Pain Beyond Treatment01:10:32 The Role of Curiosity in Pain Management01:13:08 The Global Burden of Pain and Movement01:16:26 The Complexity of Trigger Points01:20:51 Shared Decision Making in Therapy01:22:14 Exploring the Causes of Rising Pain Rates01:26:31 The Interplay of Pain, Anxiety, and Movement01:30:35 The Evolving Role of Touch in Therapy01:41:14 The Role of Touch in Movement and Pain Management01:44:28 Exploring Movement and Pain Perception01:46:41 The Interplay of Touch, Breath, and Awareness01:51:53 Understanding Pain and Movement Patterns02:01:34 The Importance of Patient Interaction and Experience02:04:02 Frameworks for Understanding Movement and Pain

Houston plastic surgeon Dr. Shannon Kuruvilla breaks down migraines, one of the leading causes of disability worldwide, especially for women under 50. Defining the different types of migraines, their triggers, and how they can disrupt daily life, Dr. Kuruvilla explains various treatment approaches, how each works and who might benefit.  From medications and lifestyle changes to Botox and surgical options, she walks through the details of migraine surgery, including who's a good candidate, expected outcomes, and the recovery process.Whether you're seeking relief through non-surgical methods or considering surgery, Dr. Kuruvilla shares insights on managing chronic migraines and regaining control of your daily life.Read more about Houston plastic surgeon Dr. Shannon KuruvillaRead more about the Global Burden of Disease studyDr. Shannon Kuruvilla is a Houston plastic surgeon specializing in aesthetic surgery of the breast, body, and face. She also offers minimally invasive migraine treatments. She connects deeply with patients by understanding their unique stories and aspirations.Basu Plastic Surgery and Aesthetics is located in Northwest Houston in the Towne Lake area of Cypress. To learn more about the practice or ask a question, go to https://www.basuplasticsurgery.com/podcast On Instagram, follow Dr. Basu and the teamhttps://instagram.com/basuplasticsurgery Behind the Double Doors is a production of The Axishttp://theaxis.io/ 

In this episode, Molly kicks off Alcohol Awareness Month by shining a light on five pervasive myths about alcohol that many people still believe—and why they matter. These aren't opinion-based takes or moralistic warnings. They're data-backed truths designed to help you reassess your relationship with alcohol through the lens of science, compassion, and practicality.Molly revisits commonly held beliefs like “red wine is good for your heart” and the idea that there's a universally “safe” level of drinking. She also unpacks the misconceptions surrounding alcohol dependence, the blurred line between moderate and excessive drinking, and why conscious choice—not unconscious habit—is the cornerstone of peaceful drinking.If you're someone who's been “justifying” your nightly pour with old headlines or fuzzy statistics, this episode is your call to reframe, recalibrate, and realign your drinking decisions with facts—not feelings.What You'll Learn in This Episode:The truth behind the red wine “heart health” narrativeWhy “moderate” drinking might not be as safe as you thinkWhat the data says about alcohol and disease riskThe reality that 9 out of 10 excessive drinkers are not alcohol dependentWhy the language we use around alcohol can keep us stuckHow science supports self-awareness over abstinence mandatesKey Quote: "It's not about shame or absolutes. It's about awareness, choice, and a willingness to meet yourself where you are—without pretending alcohol is something it's not." —Molly WattsMentioned in This Episode: Episode 111: Global Burden of DiseaseEpisode 31: Using Science to Guide Your Alcohol DecisionsAlcohol Truths 2023 (Free eBook)Breaking the Bottle Legacy (Book)Take It Further:→ Download the Alcohol Core Beliefs guide to uncover the unconscious thoughts keeping your drinking stuck. → For deeper change, explore the Making Peace with Alcohol 12-month coaching group program. Let's Connect: Website: www.mollywatts.com Instagram: @alcoholminimalist Facebook: Join the Alcohol Minimalists GroupLow risk drinking guidelines from the NIAAA:Healthy men under 65:No more than 4 drinks in one day and no more than 14 drinks per week.Healthy women (all ages) and healthy men 65 and older:No more than 3 drinks in one day and no more than 7 drinks per week.One drink is defined as 12 ounces of beer, 5 ounces of wine, or 1.5 ounces of 80-proof liquor. So remember that a mixed drink or full glass of wine are probably more than one drink.Abstinence from alcoholAbstinence from alcohol is the best choice for people who take medication(s) that interact with alcohol, have health conditions that could be exacerbated by alcohol (e.g. liver disease), are pregnant or may become pregnant or have had a problem with alcohol or another substance in the past.Benefits of “low-risk” drinkingFollowing these guidelines reduces the risk of health problems such as cancer, liver disease, reduced immunity, ulcers, sleep problems, complications of existing conditions, and more. It also reduces the risk of depression, social problems, and difficulties at school or work. ★ Support this podcast ★

Send us a textDr. Marianne Holm, MD, Ph.D. is Vice President of the Infectious Diseases Program area, at the Novo Nordisk Foundation ( https://novonordiskfonden.dk/en/ ) where she is responsible for supporting the development and implementation of new strategic initiatives and research programs, and developing partnerships that contribute to the global visibility and impact of the foundation's activities within Infectious Diseases, and this responsibility includes supporting multiple cross disciplinary initiatives in Antimicrobial Resistance (AMR).Dr. Holm is a medical doctor and epidemiologist, who previously led the department of epidemiology and public health research at the International Vaccine Institute (IVI) in Seoul, where she was responsible for the coordination and implementation of several large development programs funded by the Fleming Fund, working with local governments and healthcare institutions to build capacity in AMR surveillance in low- and middle- income countries in the Asian region. Prior to joining IVI in 2018, Dr. Holm worked for 4 years at the School of Public Health at the University of Hong Kong working in the health services research unit coordinating the School's evidence based practice education program.Dr. Holm has been a member of the coordination group of the WHO Technical Advisory Group and Coordination Group on Vaccines and AMR. She is also a member of the Global Burden of Disease (GBD) Collaborator Network as well as the Surveillance and Epidemiology of Drug Resistant Infections Consortium (SEDRIC) network.Dr. Holm received her MD and Ph.D. from University of Copenhagen and Master of Science (MSc), Epidemiology, London School of Hygiene and Tropical Medicine, U. of London.IMPORTANT EPISODE LINK - Gram-Negative Antibiotic Discovery Innovator (Gr-ADI) - https://gcgh.grandchallenges.org/challenge/innovations-gram-negative-antibiotic-discovery The Gram-Negative Antibiotic Discovery Innovator (Gr-ADI) is tripartite initiative of the Novo Nordisk Foundation, the Bill & Melinda Gates Foundation and Wellcome Trust, that will focus on discovery of direct-acting small-molecule antibiotics with broad-spectrum activity against Enterobacteriaceae (a large family of Gram-negative bacteria that includes Salmonella, Escherichia coli, Shigella and Klebsiella), with Klebsiella spp. selected as an initial targeted pathogen. Klebsiella organisms can lead to a wide range of disease states, notably pneumonia, urinary tract infections, sepsis, meningitis, diarrhea, peritonitis and soft tissue infections. The program aims to address the lack of novel antibiotics for gram-negative bacteria and the public health threat posed by antimicrobial resistance (AMR).#NovoNordiskFoundation #GramNegativeAntibioticDiscoveryInnovator #BillAndMelindaGatesFoundation #WellcomeTrust #AMR #AntimicrobialResistance #Enterobacteriaceae #Klebsiella #Salmonella #EscherichiaColi #Shigella #InfectiousDiseases #MarianneHolm #Vaccines #MultidrugEffluxPumps #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

“Good stressors are the most powerful medicine we have,” explains Sharon Horesh Bergquist, M.D. Bergquist, an award-winning physician, innovative healthcare leader, and researcher, joins us today to explain why stress is actually a good thing, how to optimize our exercise routines, plus so much more:  - The difference between good & bad stress (~2:20) - Exercise as a stressor (~3:15) - Zone 2 & HIIT (~4:45) - The 80/20 rule (~6:20) - Vigorous exercise (~11:10) - The power of intervals (~13:40) - Mitochondrial health (~15:00) - The balance between too much & not enough stress (~21:15) - The benefits of plant toxins (~24:28) - Hot/cold therapy (~30:10) - Temp & timing for cold exposure (~34:50) - Heat exposure (~43:10) - Temp & timing for heat exposure (~46:40) - Gender differences in stress exposure (~48:50) - Circadian fasting (~51:00) - Impactful takeaways (~54:45) - How to instill growth mindset in younger generations (~56:05) Referenced in the episode:  - Follow Bergquist on Instagram (@thegoodstressdoctor) - Check out her website (https://drsharonbergquist.com/)  - Pick up her book, The Stress Paradox - Research on vigorous intermittent lifestyle physical activity (https://doi.org/10.1038/s41591-022-02100-x)  - Research on interval-walking training (DOI: 10.23736/S0022-4707.22.14263-5)  - Global Burden of Disease Study (DOI: 10.1016/S0140-6736(18)32279-7)  - Research on stress & biological age (https://link.springer.com/article/10.1007/s10522-022-09985-8)  Go to get.stash.com/mindbodygreen to see how you can receive $25 towards your first stock purchase and to view important disclosures We hope you enjoy this episode, and feel free to watch the full video on YouTube! Whether it's an article or podcast, we want to know what we can do to help here at mindbodygreen. Let us know at: podcast@mindbodygreen.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

Are we talking enough about health checks and the possibility of cancer for young adults? Synopsis: The Usual Place host Natasha Ann Zachariah hunts for new perspectives on issues that matter to young people. When she was about 35 years old, stay-at-home mother Hannah Seow discovered she had breast cancer after a self-examination. Her diagnosis came about two years after her youngest child, Caleb, died. For Samuel Ng, a month-long on-and-off fever was a sign that there was a deeper issue. In January 2024, after a blood test, he got the dreaded call. His report was “unfavourable”. Soon after, he was diagnosed with acute lymphoblastic leukaemia. While dealing with cancer, he was laid off from his job. In this episode, Natasha chats with Hannah, now 37, and Samuel, 35, about how it feels to get cancer as young adults, their mindsets through their journeys, and if they want to be known as cancer survivors. According to the Singapore Cancer Registry Annual Report 2022, while cancer remains largely a disease of older age, more young people are being diagnosed with cancer. Between 2008 and 2012, the age groups with the most rapid increases in the age-specific incidence of cancer were all under 50 years old - with those aged between 30 and 39 registering the largest differences. This trend is also reflected globally, with Global Burden of Diseases data showing an increasing trend of cancer among younger age groups, with a 79 per cent increase in “early onset” – under 50 years old – cancer globally between 1990 and 2019. To celebrate the lives of those who have battled cancer and those still fighting against the disease, the Singapore Cancer Society has organised Relay For Life (RFL) once again. The annual overnight event from March 8-9 comprises a 100km physical relay event at the National Stadium, as well as a virtual challenge component. While registration for the physical relay has closed, donations to RFL remain open until March 23, 2025. Donate at www.scsrelayforlife.sg. Highlights (click/tap above): 1:32 How did Hannah and Samuel find out they had cancer? 10:39 What was it like telling people about their diagnoses?15:35 How both of them stayed positive throughout 27:46 Should Samuel disclose his cancer diagnosis to a potential employer? 33:57 Do Hannah and Samuel want to leave their cancer story out of their identities? Follow Singapore Cancer Society: https://www.instagram.com/sgcancersociety/?hl=en Host: Natasha Ann Zachariah Follow Natasha on her IG account and DM her your thoughts on this topic: https://str.sg/8Wav Follow Natasha on LinkedIn: https://str.sg/v6DNRead Natasha's articles: https://str.sg/iSXmFilmed by: Studio+65 Edited by ST Podcast producers: Teo Tong Kai & Eden Soh Executive producers: Ernest Luis & Lynda Hong Follow The Usual Place Podcast on Thursdays and get notified for new episode drops: Channel: https://str.sg/5nfm Apple Podcasts: https://str.sg/9ijX Spotify: https://str.sg/cd2P YouTube: https://str.sg/wEr7u Feedback to: podcast@sph.com.sg --- Follow more ST podcast channels: All-in-one ST Podcasts channel: https://str.sg/wvz7 ST Podcasts website: http://str.sg/stpodcasts ST Podcasts YouTube: https://str.sg/4Vwsa --- Get The Straits Times app, which has a dedicated podcast player section: The App Store: https://str.sg/icyB Google Play: https://str.sg/icyX #tup #tuptrSee omnystudio.com/listener for privacy information.

Die Themen in den Wissensnachrichten: +++ Mammutfell-Mäuse gezüchtet +++ Klimawandel bedroht Ernteerträge +++ Frauen bei Weiterbildung benachteiligt +++**********Weiterführende Quellen zu dieser Folge:Multiplex-edited mice recapitulate woolly mammoth hair phenotypes. BioRxiv. 04.03.2025Climate change threatens crop diversity at low latitudes, Nature Food, 04.03.2025UND ES GIBT IHN DOCH! Der Gender Training Gap bei betrieblichen Weiterbildungen, WSI Report, März 2025Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021, The Lancet 3.3.25Überraschender Strandfund: Historische Driftkarte von 1961 auf Juist entdeckt, Bundesamt für Seeschifffahrt und Hydrographie, 03.03.2025**********Ihr könnt uns auch auf diesen Kanälen folgen: TikTok auf&ab , TikTok wie_geht und Instagram .

Valery Feigin speaks to Pierre Nauleau about the Global Burden of Disease study on epilepsy.Read the full article, Global, regional, and national burden of epilepsy, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021, at https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(24)00302-5/fulltext?dgcid=buzzsprout_icw_podcast_lanpubContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Schickt uns eine Nachricht Die Tierseuche «Blauzungenkrankheit» breitet sich in der Schweiz aus und stellt Landwirt*innen vor grosse wirtschaftliche Herausforderungen. Seit Ende August 2024 sind bereits über 2200 Betriebe betroffen. Doch was bedeutet das konkret für Tierhalter*innen?In der aktuellen Podcastfolge gibt die FiBL Tierärztin Ariane Maeschli wertvolle Einblicke: Wie wird der Virus übertragen? Welche Schutzmassnahmen sind möglich? Und welche Massnahmen sind bei einem Ausbruch zu ergreifen?Erhöhtes Ansteckungsrisiko ab FrühlingDie Blauzungenkrankheit, eine durch Stechmücken übertragene Viruserkrankung, befällt vor allem Wiederkäuer wie Schafe und Rinder. Während der Wintermonate gibt es eine vektorfreie Periode, in der das Virus ruht – doch mit steigenden Temperaturen nimmt die Gefahr wieder zu. «Eine Prophylaxe ist wirtschaftlich sicher sinnvoll, aber auch fürs Tier, denn die Tiere leiden dann halt wirklich, wenn sie schwer krank sind», betont Maeschli.Vorbeugen und BehandelnIm Gespräch erläutert die Expertin die verschiedenen Virus-Serotypen und deren Verbreitung in der Schweiz. Sie gibt praktische Tipps zu Impfungen, komplementären Vorbeuge- und Behandlungsmethoden sowie weiteren Schutzmassnahmen. Zudem erklärt sie, woran erkrankte Tiere erkannt werden können und was bei Ausbruch der Tierseuche zu tun ist. Gästin: Ariane MaeschliWeitere Informationen Schweiz:BLV: Informationen zur BlauzungenkrankheitProjekt der IG Homöopathie Nutztiere zur Blauzungenkrankheit: Betriebe können sich ab Mitte Februar 2025 per Email an info@handbuchzurstallapotheke.ch anmelden.24h Hotline - komplementärmedizinische, telefonische Beratung KometianKosten einer Impfung gegen das Blauzungenvirus: die Tierärzteschaft ist bei der Preisgestaltung frei, üblicherweise wird pro Impfdosis 5 CHF plus MWST verrechnet (Medikamentenpreis Bultavo-3 von Böhringer), falls die Landwirt*innen nicht selbst impfen, wird diese Dienstleistung zusätzlich verrechnet.teleBaselpunkt6 vom 20.02.2025: Tierseuche zwingt Bauern zu NottötungenWeitere Informationen international:AGES: Krankheitserreger BlauzungenkrankheitEFSA: BlauzungenkrankheitBarua, S.; Rana, E.A.; Prodhan, M.A.; Akter, S.H.; Gogoi-Tiwari, J.; Sarker, S.; Annandale, H.; Eagles, D.; Abraham, S.; Uddin, J.M. The Global Burden of Emerging and Re-Emerging Orbiviruses in Livestock: An Emphasis on Bluetongue Virus and Epizootic Hemorrhagic Disease Virus. Viruses 2025, 17, 20. https://doi.org/10.3390/v17010020E-Mailpodcast@fibl.orgInstagram@fibl_focusWebsitewww.fibl.orgFiBL Focus ist der Podcastkanal des FiBL Schweiz, einem der weltweit grössten Forschungsinstitute für biologischen Landbau.

Just a few decades ago data from the Global Burden of Disease study reported about half a million people with Parkinson's disease, with its characteristic tremor at rest and other movement abnormalities. Johns Hopkins neurologist Liana Rosenthal says now more … More and more people worldwide are developing Parkinson's disease, Elizabeth Tracey reports Read More »

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Global Burden of Early-Onset Ischemic Heart Disease, 1990 to 2019.

The last Lancet Voice of the year delves into the latest findings from the Institute for Health Metrics and Evaluation (IHME) from our recently released US Special Issue. Ali Mokdad and Emmanuela Gakidou join Miriam Sabin and Gavin Cleaver to explore the comprehensive analysis of the Global Burden of Disease, the alarming trends in obesity and life expectancy, and the critical need for policy changes to improve public health in the United States.Read the US special issue here:https://www.thelancet.com/journals/lancet/issue/vol404no10469/PIIS0140-6736(24)X0050-1?dgcid=buzzsprout_tlv_podcast_generic_lancetSend us your feedback!Read all of our content at https://www.thelancet.com/?dgcid=buzzsprout_tlv_podcast_generic_lancetCheck out all the podcasts from The Lancet Group:https://www.thelancet.com/multimedia/podcasts?dgcid=buzzsprout_tlv_podcast_generic_lancetContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

In this episode, we discuss the plight of mental illness and unique risk factors for mental illness in developing countries, the poverty trap and much more... Chapters 0:00 Show Intro 1:54 Is MI a Western Problem Only? 3:10 Risk Factors in Developing Countries 8:30 Mental Health Stigma 11:30 The Poverty Trap 16:48 Possible Solutions Show Notes "The Lancet Commission on global mental health and sustainable development" by Patel et al., 2018 "Mental Health Service Provision in Low- and Middle-Income Countries" by Rathod et al., 2017 "World mental health report: Transforming mental health for all" by WHO, 2022 "Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017" "Brain drain among Sri Lankan psychiatrists" by Chandradasa and Kuruppuarachchi (2023) "Why are we still living in the past? Sri Lanka needs urgent and timely reforms of its archaic mental health laws" by Hapangama et al., 2023

ROMA (ITALPRESS) - Le malattie cardiovascolari sono la principale causa di morte in Italia con oltre 217mila decessi l'anno. Secondo le ultime stime del Global Burden of Disease, in Italia circa 9,6 milioni di individui sono affetti da malattie cardiovascolari, con 800 mila nuove diagnosi annuali e oltre 670 mila ricoveri ospedalieri imputabili a queste patologie. Nonostante l'efficacia delle terapie ipolipemizzanti, antidiabetiche e antipertensive, esiste un gruppo di pazienti che può rimanere esposto a rischio cardiovascolare residuo, ovvero la probabilità che ha una persona con malattia cardiovascolare di sviluppare nuovi eventi, spesso fatali, anche laddove trattata seguendo gli standard di cura. Al Rischio cardiovascolare residuo è dedicato un Manifesto promosso dalle società scientifiche, realizzato con il patrocinio di SID e SALUTEQUITA' e col contributo non condizionante di Amarin. Lo presenta Francesco Dentali, Presidente della Federazione delle Associazioni dei Dirigenti Ospedalieri Internisti.sat/mrv

Warning: This post discusses statistics about extreme pain that may be distressing. While cluster headaches are a neglected, high-impact issue, understanding their true burden requires appreciating the intensity of suffering involved. The pain often reaches levels far beyond typical human experience, making subjective accounts a valuable datapoint until we have robust methods for quantifying pain intensity. For further context, links to firsthand accounts are provided in the footnote[1]. You no longer have a headache, or pain located at a particular site: you are literally plunged into the pain, like in a swimming pool. There is only one thing that remains of you: your agitated lucidity and the pain that invades everything, takes everything. There is nothing but pain. At that point, you would give everything, including your head, your own life, to make it stop. - Yves, cluster headache patient from France (from Rossi et al., 2018) Key [...] ---Outline:(01:11) Key takeaways(03:57) 1. Introduction(04:00) 1.1. Clinical Features and Pain Comparisons(07:22) 1.2. Treatment and Prevention(10:02) 1.3. The Heavy-Tailed Valence Hypothesis and Existing Metrics(14:49) 1.4. Goal(16:14) 2. Methods(17:43) 2.1 Prevalence(19:17) 2.2 Frequency(22:21) 2.3 Duration(23:53) 2.4 Intensity(25:58) 2.5 Burden Metrics(29:01) 3. Results(29:10) 3.1. Global Burden of Cluster Headache Pain(32:05) 3.2. Reweighting of Extreme Pain(39:41) 3.3. Ceiling Effects(43:34) 4. Recommendations and Conclusions(48:31) AcknowledgementsThe original text contained 26 footnotes which were omitted from this narration. --- First published: November 1st, 2024 Source: https://forum.effectivealtruism.org/posts/geh2g2nKb7Kkp26ze/quantifying-the-global-burden-of-extreme-pain-from-cluster --- Narrated by TYPE III AUDIO. ---Images from the article:Apple Podcasts and Spotify do not show images in the episode description. Try Pocket Casts, or another podcast app.

The November 2024 replay features four episodes dedicated to brain health. It kicks off with an interview with Dr. Nicoline Schiess, who discusses the World Health Organization (WHO) Brain Health Unit. Next, Dr. Katrin Seeher delves into the global burden of neurological conditions and the WHO's strategies to enhance care and awareness. The third segment features Dr. Natalia Rost who introduces and highlights the American Academy of Neurology's (AAN) groundbreaking brain health initiative. The episode wraps up with Dr. Rost again, who returns to give an update and emphasize the urgency of addressing brain health amidst public health challenges. Podcast Links: WHO Brain Health Unit Global Burden of Neurologic Conditions Brain Health Initiative with Dr. Natalia Rost Update on Brain Health with Dr. Natalia Rost Article Links: Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 The Brain Health Imperative in the 21st Century—A Call to Action AAN Brain Health Initiative Disclosures can be found at Neurology.org.

When was the last time you thought about iron? It can be an easily overlooked mineral in our diet. Turns out, it deserves a little more attention and fanfare, especially for the role it plays in brain health. In today's episode we're talking all about iron, iron deficiency, and iron-deficiency anemia. What are the signs of iron deficiency? How much iron do you need? And what's the best way to get more iron in your diet?    This episode is in collaboration with the National Cattlemen's Beef Association, a contractor of the Beef Checkoff. Beef and Iron (beefitswhatsfordinner.com) Beef In the Early Years (beefitswhatsfordinner.com) Beef for Tweens and Teens (beefitswhatsfordinner.com) Nutrition (beefitswhatsfordinner.com)   Sources for this episode include: National Institutes of Health, Iron Fact Sheet for Health Professionals National Academy of Sciences, Dietary Reference Intakes Summary Tables What We Eat in America, NHANES 2017-March 2020 Prepandemic Global, regional, and national burdens of common micronutrient deficiencies from 1990 to 2019: A secondary trend analysis based on the Global Burden of Disease 2019 study Psychiatric disorders risk in patients with iron deficiency anemia and association with iron supplementation medications: a nationwide database analysis Iron Status in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis Peripheral iron levels in children with attention-deficit hyperactivity disorder: a systematic review and meta-analysis Irritability and Perceived Expressed Emotion in Adolescents With Iron Deficiency and Iron Deficiency Anemia: A Case-Control Study Stat Pearls. Biochemistry, Iron Absorption Iron Absorption: Factors, Limitations, and Improvement Methods The Effect of the Meat Factor in Animal-Source Foods on Micronutrient Absorption: A Scoping Review   Thank you for listening to The Happy Eating Podcast. Tune in weekly on Thursdays for new episodes! For even more Happy Eating, head to our website!  https://www.happyeatingpodcast.com Learn More About Our Hosts:  Carolyn Williams PhD, RD: Instagram: https://www.instagram.com/realfoodreallife_rd/ Website: https://www.carolynwilliamsrd.com Facebook: https://www.facebook.com/RealFoodRealLifeRD/ Brierley Horton, MS, RD Instagram: https://www.instagram.com/brierleyhorton/ Got a question or comment for the pod? Please shoot us a message!  happyeatingpodcast@gmail.com Produced by Lester Nuby OE Productions

Dr. Farrah Mateen and Dr. Katrin Seeher discuss the significant global burden of neurologic conditions, which affects over 3.4 billion people worldwide, and the strategies the WHO is implementing to improve care and awareness. Show reference: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(24)00038-3/fulltext#seccestitle10  

Dr. Farrah Mateen talks with Dr. Katrin Seeher about the significant global burden of neurologic conditions, which affects over 3.4 billion people worldwide, and the strategies the WHO is implementing to improve care and awareness. Read the related article in The Lancet Neurology. Disclosures can be found at Neurology.org.  

Lifestyle Behaviours in Mental Illness: 10min Lifestyle Psych Welcome to this 10 Minute Lifestyle Psychiatry episode. I discuss the mortality gap in people with serious mental illness, the underlying factors driving this and some of the solutions to this. Chapters 0:00 Show Intro 1:25 What Is the Mortality Gap Scandal? 3:20 Lifestyle Behaviours 7:55 Social Determinants of Mental Health 10:25 Diagnostic Overshadowing My name is Indi Dissanayake and I am a PhD Candidate investigating the implementation of exercise-based psychotherapy into mental healthcare, and a Provisional Psychologist. Check out the channel for deep dives into all things Lifestyle Psychiatry. I hope you find our content valuable. Show Notes -Physical health disparities and mental illness: the scandal of premature mortality (Thornicroft et al., 2011) -Diagnostic overshadowing and other challenges involved in the diagnostic process of patients with mental illness who present in emergency departments with physical symptoms--a qualitative study (Schefer et al., 2014) -Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders (Galletly et al., 2016) -Smoking and Mental Illness. A Population-Based Prevalence Study (Lasser et al., 2000) -Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis (Walker et al., 2015) -Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016 (Charlson et al., 2018)

This is a link post. One of Open Philanthropy's goals for this year is to experiment with collaborating with other funders. Today, we're excited to announce our biggest collaboration to date: the Lead Exposure Action Fund (LEAF). Lead exposure in low- and middle-income countries is a devastating but highly neglected issue. The Global Burden of Disease study estimates 1.5 million deaths per year attributable to lead poisoning. Despite this burden, lead poisoning has only received roughly $15 million per year in philanthropic funding until recently. That is less than 1% of the funding that goes towards diseases like tuberculosis or malaria, which are themselves considered neglected. The goal of LEAF is to accelerate progress toward a world free of lead exposure by making grants to support measurement, mitigation, and mainstreaming awareness of the problem. Our partners have already committed $104 million, and we plan for LEAF to allocate that [...] ---Outline:(01:54) Why we chose to work on lead(04:54) What LEAF hopes to achieve(05:30) The LEAF team(06:01) An experiment for Open Philanthropy(06:49) Grantmaking so farThe original text contained 3 footnotes which were omitted from this narration. --- First published: September 23rd, 2024 Source: https://forum.effectivealtruism.org/posts/z5PvTSa54pdxxw72W/announcing-the-lead-exposure-action-fund --- Narrated by TYPE III AUDIO.

Host: Jennifer Caudle, DO Guest: Samuel R. Wilson, MD Sickle cell disease is among the most common inherited conditions globally, affecting more than seven million individuals worldwide.1-3 Given its prevalence, it is important to understand all of the complexities surrounding this disease. Joining Dr. Jennifer Caudle to discuss the pathophysiology, clinical presentation, burden, and unmet needs of sickle cell disease is Dr. Samuel R. Wilson, Assistant Professor of Medicine in the Division of Hematology at the University of North Carolina School of Medicine. References: Sedrak A, Kondamudi NP. Sickle cell disease. StatPearls Publishing; 2023. Updated August 12, 2023. Accessed April 16, 2024. https://www.ncbi.nlm.nih.gov/books/NBK482384/. Thomson AM, McHugh TA, Oron AP, et al. Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000–2021: a systematic analysis from the Global Burden of Disease Study 2021. Lancet Haematol. 2023;10(8):e585-e599. doi:10.1016/S2352-3026(23)00118-7. CDC. Data & statistics on sickle cell disease. Centers for Disease Control and Prevention. Published May 2, 2022. Accessed April 16, 2024. https://www.cdc.gov/ncbddd/sicklecell/data.html/. Agios Pharmaceuticals, Inc. © 2024 All right reserved.SCD-US-0095 / June 2024

Host: Jennifer Caudle, DO Guest: Samuel R. Wilson, MD Sickle cell disease is among the most common inherited conditions globally, affecting more than seven million individuals worldwide.1-3 Given its prevalence, it is important to understand all of the complexities surrounding this disease. Joining Dr. Jennifer Caudle to discuss the pathophysiology, clinical presentation, burden, and unmet needs of sickle cell disease is Dr. Samuel R. Wilson, Assistant Professor of Medicine in the Division of Hematology at the University of North Carolina School of Medicine. References: Sedrak A, Kondamudi NP. Sickle cell disease. StatPearls Publishing; 2023. Updated August 12, 2023. Accessed April 16, 2024. https://www.ncbi.nlm.nih.gov/books/NBK482384/. Thomson AM, McHugh TA, Oron AP, et al. Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000–2021: a systematic analysis from the Global Burden of Disease Study 2021. Lancet Haematol. 2023;10(8):e585-e599. doi:10.1016/S2352-3026(23)00118-7. CDC. Data & statistics on sickle cell disease. Centers for Disease Control and Prevention. Published May 2, 2022. Accessed April 16, 2024. https://www.cdc.gov/ncbddd/sicklecell/data.html/. Agios Pharmaceuticals, Inc. © 2024 All right reserved.SCD-US-0095 / June 2024

Commentary by Dr. Valentin Fuster

BUFFALO, NY- June 10, 2024 – A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 10, entitled, “Relationships of depression and antidepressant use with epigenetic age acceleration and all-cause mortality among postmenopausal women.” In this new study, researchers May A. Beydoun, Hind A. Beydoun, Jason Ashe, Michael F. Georgescu, Steve Horvath, Ake Lu, Anthony S. Zannas, Aladdin H. Shadyab, Su Yon Jung, Sylvia Wassertheil-Smoller, Ramon Casanova, Alan B. Zonderman, and Robert L. Brunner from the National Institute on Aging, U.S. Department of Veterans Affairs (Washington, DC), University of Texas Health Science Center at Houston, University of California Los Angeles, University of North Carolina at Chapel Hill, University of California San Diego, Albert Einstein College of Medicine, Wake Forest University School of Medicine, and University of Nevada Reno investigated relations of depressive symptoms, antidepressant use, and epigenetic age acceleration with all-cause mortality risk among postmenopausal women. “Frequently under-recognized depression is a major contributor to the Global Burden of Diseases [1, 2] while being the most prevalent mental illness among geriatric populations [2].” Data were analyzed from ≤1,900 participants in the Women's Health Initiative study testing four-way decomposition models. After a median 20.4y follow-up, 1,161 deaths occurred. Approximately 11% had elevated depressive symptoms (EDS+), 7% were taking antidepressant medication at baseline (ANTIDEP+), while 16.5% fell into either category (EDS_ANTIDEP+). Baseline ANTIDEP+, longitudinal transition into ANTIDEP+ and accelerated epigenetic aging directly predicted increased mortality risk. GrimAge DNA methylation age acceleration (AgeAccelGrim) partially mediated total effects of baseline ANTIDEP+ and EDS_ANTIDEP+ on all-cause mortality risk in socio-demographic factors-adjusted models (Pure Indirect Effect >0, P < 0.05; Total Effect >0, P < 0.05). Thus, higher AgeAccelGrim partially explained the relationship between antidepressant use and increased all-cause mortality risk, though only prior to controlling for lifestyle and health-related factors. “Antidepressant use and epigenetic age acceleration independently predicted increased all-cause mortality risk. Further studies are needed in varying populations.” DOI - https://doi.org/10.18632/aging.205868 Corresponding author - May A. Beydoun - baydounm@mail.nih.gov Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.205868 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, depressive symptoms, epigenetic age acceleration, mortality About Aging-US Aging publishes research papers in all fields of aging research, including but not limited to aging processes (from yeast to mammals), cellular senescence, age-related diseases (such as cancer and Alzheimer's disease) and their prevention and treatment, anti-aging strategies and drug development, and, importantly, the role of signal transduction pathways in aging (such as mTOR) and potential approaches to modulate these signaling pathways to extend lifespan. Please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

Life expectancy is expected to increase by almost five years around the world by 2050, according to new research. The Global Burden of Disease Study says countries with lower life expectancy are expected to see the biggest increases.Claudia Hammond is joined by BBC Africa health correspondent Dorcas Wangira to hear how public health measures are behind the predicted increases.We also hear about how negotiations at this week's World Health Assembly to secure a global deal for countries to prepare for pandemics have fallen through.Claudia and Dorcas discuss new research in Kenya into the time of day mosquitoes are biting children in school, and what it tells us about whether the insects are getting smarter.We also hear about the project twinning hospitals in Mexico and the US to try to improve the survival chances of children with leukaemia.And new research from Australia suggests having a baby takes much more metabolic energy than previously thought. Presenter: Claudia Hammond Producer: Dan Welsh Editor: Holly Squire

Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: Introducing Ansh: A Charity Entrepreneurship Incubated Charity, published by Supriya on May 29, 2024 on The Effective Altruism Forum. Executive Summary Ansh, a 1-year-old Charity Entrepreneurship incubated charity, has been delivering an evidence-based, scientifically proven intervention called Kangaroo Care to low birth weight and premature babies in 2 government hospitals in India since January 2024. Ansh estimates that their programs are saving, on average, 4 lives a month per facility and a total of 98 lives per year. The cost of one life saved is approximately $2077 (current costs, not a potential estimate). Ansh is now replicating the programs in two additional hospitals, doubling their impact before the end of this year. According to the World Health Organization (WHO), neonatal conditions[1] are among the top 10 causes of death worldwide[2]. This makes neonatal mortality one of the largest-scale causes of suffering and death today. In 2022, 2.3 million babies died in the first 28 days of life (i.e. the newborn/neonatal period) (World Health Organisation, 2024). Let's compare that number to one of EA's other top cause areas. In 2022, 608,000 people died of malaria, which is about 26.4% lower than neonatal conditions. However, we have a cost-effective, scalable model for preventing malaria-caused death (e.g., with AMF and Malaria Consortium). Unfortunately, there has been no equivalently cost-effective and scalable model for preventing neonatal mortality. In this post, we will introduce Ansh, a 1-year-old Charity Entrepreneurship incubated charity that is working towards building tractable, scalable solutions to neonatal mortality in low- and middle-income countries (LMICs). 81% of neonatal deaths happen in low and Low-Middle SDI countries. The disparities in mortality rates between low and high-resource contexts suggest that most neonatal deaths are preventable. In the sections below, we will first introduce Ansh and its mission statement, share our results thus far, and then introduce some of our plans for how to increase our reach and impact over the next few years. We are very excited to share the work we've done so far with the EA community, and to hear your constructive feedback on how we can make our non-profit even more impactful! I. The Problem and Solution More than half of all neonatal deaths occur within the first three days after birth (Dol J, 2021) and over 75% in the first week of life (WHO, 2024), making it imperative to reach babies as soon after birth as possible. Moreover, low birth weight (LBW)[3] is considered the number one mortality risk factor for children under 5. In fact, according to the Global Burden of Disease, around 89% of all newborn deaths in India (the country where about 22% of all newborn deaths in the world occur) happen to LBW and preterm newborns. Further, 81% of all newborn deaths occur in Low or Low-Middle SDI countries (Global Burden of Disease Collaborative Network, 2019). Hence, the most effective path toward reducing neonatal mortality rates globally lies in developing interventions aimed at helping LBW babies during their first week of life in LMIC contexts. Thankfully, such an intervention exists: Kangaroo Care. Kangaroo Care (KC) needs neither fancy equipment nor expensive technology - the methods of KC are both simple and highly effective, especially for LBW newborns. KC requires early, continuous, and prolonged skin-to-skin contact between the mother (or another caregiver) and the baby for about 8 hours of contact per day-paired with exclusive breastfeeding and close monitoring of the baby. This is often assisted with a cloth binder, between the LBW newborn and caregiver (preferably the mother), to allow for mobility. Estimates from the 2016 Cochrane review suggest that KC can reduce LBW neonates' chance of (i) ...

With fast food prices increasing, a LendingTree survey found that 8/10 Americans now see this type of food, which for many is the only food they consume, as a “luxury.” It is not unrealistic to consider that we may experience the first starvation of a population despite grocery shelves being full, simply because the average person is confused, afraid, and uneducated about basic foods and how to purchase or prepare them. The Global Burden of Disease study, financed by the Bill and Melinda Gates foundation, found that by reducing consumption of certain foods and increasing consumption of others we could live healthier lives, eliminate disease, and live longer, not to mention save money on healthcare. The massive study found that the a SAD is what is primarily killing westerners. Results show that limiting focus on animal products and instead eating beans, legumes, nuts and seeds, vegetables, and fruits, can help everyone become healthier. However, people like Gates ignore that evidence and instead promote genetically modified, chemically laced, alternative plant products, not to keep us healthy but to ‘save the planet'. Instead of whole foods for health, it's synthetic un-whole foods for the planet. Something is not right here, and it starts with ignoring the science and trolling real nutrition in pursuit of profit and control. -FREE ARCHIVE & RSS: https://www.spreaker.com/show/the-secret-teachingsTwitter: https://twitter.com/TST___RadioFacebook: https://www.facebook.com/thesecretteachingsWEBSITE (BOOKS, RESUBSCRIBE for early show access): http://thesecretteachings.infoPaypal: rdgable@yahoo.comCashApp: $rdgableBuy Me a Coffee: https://www.buymeacoffee.com/tstradioSUBSCRIBE TO NETWORK: http://aftermath.mediaEMAIL: rdgable@yahoo.com / TSTRadio@protonmail.com

Today, you'll learn about an artificial reef that could save the shore from storms, how simply owning a pair of glasses can make you earn more income, and how air conditioners could help CSI detectives solve crimes. Artificial Reef “Artificial reef designed by MIT engineers could protect marine life, reduce storm damage.” by Jennifer Chu. 2024. “Coastal Protection.” Coral Reef Alliance. 2024. “Architected materials for artificial reefs to increase storm energy dissipation.” by Edvard Ronglan, et al. 2024. Glasses & Income “Having the right glasses could boost earning power by a third, Bangladesh study shows.” by Sarah Johnson. 2024. “The effect on income of providing near vision correction to workers in Bangladesh: The THRIVE (Tradespeople and Hand-workers Rural Initiative for a Vision-enhanced Economy) randomized controlled trial.” by Farzana Sehrin, et al. 2024. “Presbyopia.” Mayo Clinic. 2021. “The Global Burden of Potential Productivity Loss from Uncorrected Presbyopia.” by Kevin D. Frick, et al. 2015. AC DNA “Cold case: DNA in airconditioners to place suspects at the scene of a crime.” by Ben Coxworth. 2024. “Up in the air: Presence and collection of DNA from air and air conditioner units.” by Mariya Goray, et al. 2024. Follow Curiosity Daily on your favorite podcast app to get smarter with Calli and Nate — for free! Still curious? Get exclusive science shows, nature documentaries, and more real-life entertainment on discovery+! Go to https://discoveryplus.com/curiosity to start your 7-day free trial. discovery+ is currently only available for US subscribers. Hosted on Acast. See acast.com/privacy for more information.

Le nombre de diabétiques a quadruplé depuis les 30 derrières années... mais ça vient d'où le diabète ? Adhérez à cette chaîne pour obtenir des avantages : https://www.youtube.com/channel/UCN4TCCaX-gqBNkrUqXdgGRA/join Video tournée avec le Dr Gilbert Bou Jaoudé, médecin sexologue et andrologue. Consultez son site sur Youtube: https://www.youtube.com/@Charlesco Script: Françoise Dulong et équipe Charles.co Montage: Charles.co Pour soutenir la chaîne, au choix: 1. Cliquez sur le bouton « Adhérer » sous la vidéo. 2. Patreon: https://www.patreon.com/hndl Musique issue du site : epidemicsound.com Images provenant de https://www.storyblocks.com Abonnez-vous à la chaine: https://www.youtube.com/c/LHistoirenousledira Les vidéos sont utilisées à des fins éducatives selon l'article 107 du Copyright Act de 1976 sur le Fair-Use. Sources et pour aller plus loin: Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021” GBD 2021 Diabetes Collaborators, June 22, 2023 Dictionnaire Larousse https://www.larousse.fr/dictionnaires/francais/diabète/25108 Le texte médical du Papyrus Ebers Transcription hiéroglyphique, translittération, traduction, glossaire et index, Bernard Lalanne et Gérard Métra. 2017 Coll. Langues et cultures anciennes. Celse, traité de la médecine en 8 livres, (traduction par Charles des Etangs) Paris, Dubocher, Le Chevalier et cie., 1846. Livre IV, Ch XX, par 2, p118 RENAUD M.L. Traité des signes, des causes et de la cure des maladies aigües et chroniques; ouvrage d'Aréthée (traduit du grec) 1 volume in-80,XVIII-422IV pages. Paris, Lagny, 1834 DAREMBERG Ch. Œuvres anatomiques, physiologiques et médicales de Galien (traduction française) 2 volumes in-80, XVI-706 et 784 pages, Paris, Baillière, 1856 Histoire illustrée du diabète, de l'Antiquité à nos jours, J-J. Peumery, Les éditions Roger Dacosta, Paris, déc 1987 A Bouchardat , Diabète sucré, son traitement hygiénique , Paris, 1883 J.A. Leouffre, De la glycosurie ou diabète sucré, Paris, 1854, no 259, 55 pages Regimen sanitaris, Arnaldus de Villanova, Lyon, 1504 https://collections.nlm.nih.gov/catalog/nlm:nlmuid-2211085R-bk Dictionnaire de l'encyclopediae universalis, 2023 https://www.universalis.fr/atlas/ Histoire du diabète, Ph. Vague et B. Vialettes Hôpital du Petit-Arbois. Centre hospitalo-universitaire de Marseille. 13290 Les Milles. Nicolas, Pierre-François et Gueudeville Victor, Recherches et expériences médicales sur le diabète sucré et la phthisurie sucrée, 1 volume in-80, 99 pages, Paris, Méquignon, 1803 Le diabète dans le monde : classement par pays, 26 Oct 2022 https://www.dbl-diabete.fr/tout-sur-le-diabete/societe/classement-diabete-pays-monde Qu'est-ce que le diabète, Nov 2021 https://www.diabete.qc.ca/le-diabete/informations-sur-le-diabete/quest-ce-que-le-diabete/ Vins de Bourgogne, lexique https://www.vins-bourgogne.fr/glossaire/austere,2530,9410.html?&args=Y29tcF9pZD0xNTU5JmFjdGlvbj12aWV3R2xvc3NhaXJlJmlkPSZtb3Q9NzB8#_ La langue française, dictionnaire https://www.lalanguefrancaise.com/dictionnaire/definition/leucophlegmatie The Starvation Treatment of Diabetes par Lewis Webb Bill, M.D. et Rena S. Eckman, diététicienne. 1915. Le diabète sucré https://fr.wikipedia.org/wiki/Diabète_sucré Traité du diabète sucré, des affections gastriques et des maladies qui en dépendant, par John Rollo, traduit de l'anglais par Alyon, 1 volume in-80. Paris, Montardier-Cérioux, An VI (1797) Fédération française des diabétiques https://www.federationdesdiabetiques.org/information/recherche-innovations-diabete/decouverte-insuline#:~:text=Sur%20la%20piste%20de%20l%27insuline&text=L%27étudiant%20en%20médecine%20allemand,nom%20%3A%20les%20îlots%20de%20Langerhans Diabète Québec https://www.diabete.qc.ca/le-diabete/informations-sur-le-diabete/quest-ce-que-le-diabete/ HISTOIRE DU DIABÈTE AUX TEMPS ANCIENS: Diabète dans tous ses états, le 22/08/2022, Marc Gozlan https://www.le-diabete-dans-tous-ses-etats.precidiab.org/histoire-du-diabete/histoire-du-diabete-aux-temps-anciens/ Le taux mondial du diabète augmenteront de 529 millions cas à 1,3 milliard cas par 2050 On s'attend que chaque pays du monde verra une augmentation des taux. SEATTLE, Wash. 22 juin 2023 https://www.healthdata.org/sites/default/files/files/images/news_release/2023/French_GBD%202021%20Diabetes%20News%20Release.pdf Événement historique national de la découverte de l'insuline, 2022-12-01 https://parcs.canada.ca/culture/designation/evenement-event/decouverte-insuline-insulin-discovery# Diabète https://www.paho.org/fr/sujets/diabete#:~:text=Le%20nombre%20des%20personnes%20atteintes,%25%20en%202014%20(1) Un portrait complet du diabète de type 1 dans le monde, 2022 https://ici.radio-canada.ca/nouvelle/1923169/diabete-de-type-1-portrait-complet-planete Autres références disponibles sur demande.

Is there a vaccine for bird flu? Can pets get bird flu? Is America prepared for another pandemic? What is an example of a DALY? Why is global health security important? Our guest is AMA's Vice President of Science, Medicine and Public Health, Andrea Garcia, JD, MPH. American Medical Association CXO Todd Unger hosts.

Dr. Deanna Saylor and Prof. Mayowa Owolabi discuss reducing the global burden of stroke.  Show reference:  https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00277-6/fulltext

Dr. Deanna Saylor talks with Prof. Mayowa Owolabi about reducing the global burden of stroke. Read the related article in Lancet Neurology. 

You may have heard that high blood pressure, or hypertension, is a “silent killer.” Today, Rip unpacks what that means and how ingesting too much sodium leads to serious problems. High blood pressure, also called hypertension, is known as a “silent killer” because in most cases it has no symptoms. People with elevated blood pressure are straining their hearts by making them work harder to move blood around. Their hearts sweat and pound and gasp away, but they're none the wiser. For this reason, the Global Burden of Disease Study, which involved more than 300 institutions in 50 countries, concluded that high blood pressure is the number-one world-wide risk factor for death, resulting in fatal heart attacks, strokes, and other catastrophic organ failures.Learn why in this short minisode. Join the FREE PLANTSTRONG 7-Day Challenge: https://plantstrongfoods.com/pages/plantstrong-seven-day-challengeUpcoming Events:Black Mountain Retreat - April 14th-19th, 2024 - Save $200 with code: RIP200https://plantstrongfoods.com/pages/2024-black-mountain-retreat Sedona Retreat - October 8th-13th, 2024 - Save $200 with code: RIP200https://plantstrongfoods.com/pages/2024-sedona-retreat Follow PLANTSTRONG and Rip Esselstynhttps://plantstrongfoods.com/ https://www.facebook.com/GoPlantstrong https://www.instagram.com/goplantstrong/https://www.instagram.com/ripesselstyn/ Leave Us a Voicemail Question or StoryLeave us a voicemail: https://www.speakpipe.com/plantstrong Let Us Help Your PLANTSTRONG Journeyhttps://home.mealplanner.plantstrong.com/ https://myplantstrong.com/b/trailblazer Follow the PLANTSTRONG Podcast and Give the Show a 5-star RatingApple PodcastsSpotifyTheme Music for Episodehttps://app.soundstripe.com/songs/10845

Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: Why EA should (probably) fund ceramic water filters, published by Bernardo Baron on January 3, 2024 on The Effective Altruism Forum. Epistemic status: after researching for more than 80 hours each, we are moderately certain that ceramic filters (CFs) can be more cost-effective than chlorination to prevent waterborne diseases at least in some - and possibly in many - LMICs. We are less certain of the real size of the effects from CFs, and how some factors like household sizes affect the final cost-effectiveness. At least 1.7 billion people globally used drinking water sources contaminated with feces in 2022, leading to significant health risks from waterborne enteric infections. According to the Global Burden of Disease (GBD) 2019 study, more than 2.5% of total DALYs lost that year were linked to unsafe water consumption - and there is some evidence that this burden can be even bigger. This makes the improvement of access to clean water a particularly pressing problem in the Global Health and Development area. As a contribution to target this problem, we have put together a report on ceramic water filters as a potential intervention to improve access to safe water in low and medium income countries. This was written during our time as research fellows at Charity Entrepreneurship's Research Training Program (Fall 2023). In this post, we summarize the main findings of the report. Nonetheless, we invite people interested in the subject to check out the full report, which provides much more detail into each topic we outline here. Key takeaways: There are several (controlled, peer-reviewed) studies that link the distribution of ceramic filters to less frequent episodes of diarrhea in LMICs. Those studies have been systematically reviewed and graded low to medium quality. Existing evidence supports the hypothesis that ceramic filters are even more effective than chlorination to reduce diarrhea episodes. However, percentage reductions here should be taken with a grain of salt due to lack of masking and self-report and publication biases. Despite limitations in current evidence, we are cautiously optimistic that ceramic filters can be more cost-effective than chlorination, especially in countries where diarrheal diseases are primarily caused by bacteria and protozoa (and not by viruses). Average household sizes can also play a role, but we are less certain on the extent to which this is true. We provide a Geographic Weighted Factor Model and a country-specific back-of-the envelope analysis of the cost-effectiveness for a hypothetical charity that wants to distribute free ceramic filters in LMICs. Our central scenario for the cost-effectiveness of the intervention in the top prioritized country (Nigeria) is $8.47 U.S. dollars per DALY-averted. We ultimately recommend that EA donors and meta-organizations should invest at least some resources in the distribution of ceramic filters, either by bringing up new charities in this area, or by supporting existing, non-EA organizations that already have lots of expertise in how to manufacture, distribute and monitor the usage of the filters. Why ceramic filters? There are plenty of methods to provide access to safe(r) water in very low-resource settings. Each one of those has some pros and cons, but ceramic filters stand out for being cheap to make, easy to install and operate, effective at improving health, and durable (they are said to last for a minimum of 2 years). In short, a ceramic filter is a combination of a porous ceramic element and a recipient for the filtered water (usually made of plastic). Water is manually put into the ceramic part and flows through its pores due to gravity. Since pores are very small, they let water pass, but physically block bigger particles - including bacteria, protozoa and sediments - from passing....

Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: Road safety: Landscape of the problem and routes to effective policy advocacy, published by Rethink Priorities on November 29, 2023 on The Effective Altruism Forum. Editorial note This report was produced by Rethink Priorities between May and July 2023. The project was commissioned and supported by Open Philanthropy, which does not necessarily endorse our conclusions. This report builds on a short investigation conducted by Open Philanthropy in 2022, which found that previous philanthropic work on road safety looked potentially cost-effective. This report extends that analysis through in-depth case studies, expert interviews, cost-effectiveness modeling, and research into risk factors, the funding landscape, and promising interventions. We have tried to flag major sources of uncertainty in the report, and are open to revising our views based on new information or further research. Key takeaways Executive Summary According to the 2019 Global Burden of Disease (GBD) study, there were about 1.2 million deaths due to road injuries in 2019. About 90% of these take place in LMICs, and the majority of those killed are between 15 - 50 years old. Additionally, WHO analysis and expert interviews indicate that road safety laws in many LMICs do not meet best-practice.[1] While there is limited information about what risk factors contribute most to the road safety burden, or what laws are most important to pass, the available evidence points to speed on the roads as most risky, followed by drunk driving. We conducted case studies of key time periods in China and Vietnam to better understand the relative impact of (philanthropically-funded) policy changes versus other factors. Our assessment of China is that we think Bloomberg's implementing partners contributed minimally to the key drunk driving policy change in 2011, and we think it's likely that this law was only one of many drivers to reduce burden. In contrast, we think laws were a more important driving force in Vietnam, and advocacy by Bloomberg, the Asia Injury Prevention Foundation and others significantly sped up their introduction. We did not find any sources that gave insight into drivers on a global scale. Regarding future burden, it's likely that this will follow trends in motorization. Self-driving cars may mitigate burden as they become more common; one source estimates they could constitute 20% of the global market by 2040, though we expect this to be lower in LMICs. This report builds on a short unpublished investigation conducted by Open Philanthropy in 2022. A quick BOTEC from that report, based on an existing impact evaluation (Hendrie et al., 2021), suggested that Bloomberg's road safety initiative might be quite cost-effective enough (ROI: ~1,100x). This report extends that analysis by reviewing Hendrie et al.'s estimates of lives saved, and comparing the authors' estimates for China and Vietnam to data on road outcomes from multiple sources. For China, we found that while the data shows reduced fatalities after 2011, we could not link them specifically to fewer incidents of drunk driving. For Vietnam, quantitative evidence for the impact of the helmet laws was stronger than for the drunk driving laws. As can be seen in our BOTEC, this analysis led us to reduce the estimated effectiveness of policy changes by 40% - 80%. In addition, we used our case studies to estimate specific speed up parameters for advocacy of 0.4 years in China and 3.8 years in Vietnam, versus the 10 years used previously. These changes significantly reduce our estimate of lives saved to 17% of Open Philanthropy's previous estimate. If we use the same methodology as the previous estimate (i.e., divide this estimate by 259 million USD, the entirety of Bloomberg's spending between 2007 - 2020), then the ROI drops to 148x. However, we propo...

Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: Kaya Guides- Marginal Funding for Tech-Enabled Mental Health in LMICs, published by RachelAbbott on November 26, 2023 on The Effective Altruism Forum. This post was written by Rachel Abbott, Kaya Guides' founder. TLDR Who we are: Kaya Guides is a global mental health charity incubated by Charity Entrepreneurship. We operate a self-help program on WhatsApp to reduce depression at scale in LMICs, focusing on youth with moderate to severe depression Status: We launched in India this year and are running an ongoing proof of concept with 111 people How it works: A WhatsApp chatbot delivers videos in Hindi that teach participants evidence-based techniques to reduce depression. Participants practice the techniques day-to-day and have a 15-minute weekly call with a trained supporter for 5-8 weeks Evidence base: Self-help combined with low-touch human support can have the same effects as face-to-face psychotherapy in reducing depression, even if total staff time is less than two hours per participant What we've done: This year, we adapted the World Health Organization's digital self-help program to India's context, built a WhatsApp chatbot, produced 40 videos in Hindi, and launched our ongoing proof of concept Impact: Delivering on WhatsApp means we can reach those who need it most, at a large scale. The WHO program, studied in two RCTs, had moderate to large effects on depression Initial findings: Mental health organizations usually struggle with recruitment, but we got 875 people to message the chatbot in 1 month (similar organizations report getting 1K users in a year), achieved a 12.69% conversion rate from initial message to appearing in a guidance call, and only spent $0.95 per acquisition Cost-effectiveness: Kaya has the potential to increase subjective well-being 30x as cost-effectively as direct cash transfers by Year 3 Scaling potential: As a tech initiative, we can scale rapidly and believe we can treat 100K people in Year 5 2024 plans: Next year, we'll: 1) 10x our impact from this year by treating 1K youth with depression and 2) Establish the product, team and systems we need to scale rapidly from 2025 onward What we need: We're raising $80K to meet our 2024 budget of $160K, having so far raised $80K from the EA Mental Health Funding Circle What is Kaya Guides and what do we do? Kaya Guides is a global mental health charity incubated by Charity Entrepreneurship. Our focus is on reducing depression at scale in low and middle-income countries, beginning with India. Youth with moderate to severe depression are our target group. We deliver a self-help course via WhatsApp that teaches youth evidence-based techniques to reduce depression. During the 5-8 week course, participants have 15-minute weekly calls with trained supporters and practice the techniques day-to-day. This treatment approach (self-help, plus low-touch human support) is called guided self-help. It was recommended by Charity Entrepreneurship due to its high projected cost-effectiveness. Research indicates that guided self-help has the same effects as face-to-face psychotherapy- even if human support is only 15 minutes per week, the supporter has no clinical background, and the program lasts just five weeks. Why should we care about mental health? Mental health disorders account for 5% of global disease burden and 15% of all years lived with disability. This figure is an underestimate: the Global Burden of Disease counts suicide as an injury, even though an estimated 60-98% of suicides are attributable to mental health conditions and 700,000 people die by suicide each year. Depression and anxiety alone account for 12 billion workdays lost annually. Despite the need for expanded mental healthcare, on average just 2% of government health budgets go to mental health. Scale of the problem in India We selected...

In 2005, German gynaecologist Dr Frank Hoffmann, started his quest for a suitable medical assistant to conduct clinical breast exams for his clinic in Duisburg in Germany. By 2010, he had set up a social enterprise called Discovering Hands that trains blind and visually impaired women to conduct specialised routine breast examinations called tactile breast examinations. Today, Discovering Hands is spread across Germany, Switzerland, Austria and India, training blind and visually impaired women for the role of Medical Tactile Examiners (MTEs) who can offer accurate breast cancer screening with their highly sensitive and trained touch. The first episode in this two-part podcast series is about the problems associated with breast cancer in India and the solution MTEs offer.  In the episode, hear from Dr. Frank Hoffmann, Meenakshi Gupta, Sonal Prakash, Dr. Mandeep Malhotra, Dr. Kanchan Kaur, Dr. Lily Gutnik, Dr Poovamma CU, Shanti Raghavan, Dr. Vrutika Patel, Asha Sharma and Shashi Menon. This mini-serires has been reported by Priti Salian and the project was funded by the European Journalism Centre, through the Global Health Security Call. This programme is supported by the Bill & Melinda Gates Foundation.  Transcript: Blind and visually impaired women are emerging as a workforce in early breast cancer detection part 1.pdf  References NAB India Centre for Blind Women & Disability Studies The burden of cancers and their variations across the states of India: the Global Burden of Disease Study 1990–2016 - The Lancet Oncology Breast cancer in India: Present scenario and the challenges ahead - PMC https://journals.lww.com/jfmpc/Fulltext/2022/11000/Status_of_cancer_screening_in_India__An_alarm.106.aspx Survival Analysis of Breast Cancer Patients Treated at a Tertiary Care Centre in Southern India - ScienceDirect Breast cancer in India: Present scenario and the challenges ahead - PMC Status of cancer screening in India: An alarm signal from the National Family Health Survey (NFHS-5) See sunoindia.in/privacy-policy for privacy information.

In this episode Sal, Adam & Justin speak with Shawn Stevenson, author of Sleep Smarter, Eat Smarter, and the new Eat Smarter Family Cookbook.  Learning along the way as a parent. (2:29) “Life doesn't call the qualified. Life qualifies the called.” (5:50) We are a product of our environment but also CREATORS of it. (11:17) Fighting his way through life. (19:39) “What can I do to feel better?” His transformation moment with his health. (28:11) The three things he did to change his health. (36:31) Taking his education into his own hands. (41:31) Tackling the seed oil debate. (50:26) Looking at alternative forms of medicine for clues or hints that science hasn't looked at yet. (58:49) Why an individual approach is the best. (1:05:56) How your culture controls your choices. (1:09:36) Steps to create a healthier micro-culture in your household. (1:22:16) The impetus behind his new book and what makes it different. (1:36:24) Challenging your children through ‘safe stressors'. (1:47:12) Exposing your children to different environments so they can learn from other voices. (1:54:32) Related Links/Products Mentioned Eat Smarter Family Cookbook: 100 Delicious Recipes to Transform Your Health, Happiness, and Connection – Book by Shawn Stevenson Limited time offer exclusively for Mind Pump Listeners ONLY: 50% off the Stress, Mood & Metabolism At-Home Lab Test + Health Coaching Call – Reserve yours today here October Promotion: MAPS Bands | The Skinny Guy ‘hardgainer' Bundle 50% off! **Code OCTOBER50 at checkout** What Effect Do Questions Have On Our Brain? - Medium Racehorse Bone Health: From a Nutritional Perspective Chronic Diseases in America | CDC Importance of EPA and DHA Blood Levels in Brain Structure and Function Consumption of ultra-processed foods and associated ... - BMJ Open Trends in Consumption of Ultraprocessed Foods Among US Youths Aged 2-19 Years, 1999-2018 Omega-6 vegetable oils as a driver of coronary heart disease: the oxidized linoleic acid hypothesis In vivo respiratory toxicology of cooking oil fumes: Evidence, mechanisms and prevention Adult Obesity Facts | Overweight & Obesity | CDC  The Past 200 Years in Diabetes | NEJM Health effects of dietary risks in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 Sleep Smarter – Book by Shawn Stevenson The Benefit of Family Dinner | Harvard Graduate School of Education Is Frequency of Shared Family Meals Related to the Nutritional Health of Children and Adolescents? We Need a New Approach to Prevent Obesity in Low-Income Minority Populations Mind Pump Podcast – YouTube Mind Pump Free Resources Featured Guest/People Mentioned Shawn Stevenson (@shawnmodel) Instagram   Website Bedros Keuilian (@bedroskeuilian) Instagram Bruce H. Lipton, PhD Layne Norton, Ph.D. (@biolayne) Instagram Paul Saladino, MD (@paulsaladinomd) Instagram Arthur Brooks (@arthurcbrooks) Instagram Jim Kwik (@jimkwik) Instagram Mark Bell (@marksmellybell) Instagram  

Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: Understanding the two most common mental health problems in the world, published by spencerg on July 7, 2023 on The Effective Altruism Forum. Co-authored with Amanda Metskas This is a linkpost from ClearerThinking.org. We've included some excerpts of the article below, but you can read the full post here. Chances are, your life has been impacted by anxiety disorders or depression, either through your direct experience or through the impact they have had on your loved ones. Anxiety and depression are the two most common mental health conditions in the world, but they are frequently misunderstood. Previous EA Mental Health surveys (2023, 2021, and 2018) have also highlighted the importance of these topics to people in the community who take the surveys. In this data-based essay, we aim to help you better understand anxiety and depression, as well as the hidden links between them. By improving your understanding of these disorders, you may find it easier to recognize anxiety and depression in yourself and be more effective at supporting people in your life who experience these conditions. This infographic summarizes some of our interesting findings about the differences and similarities between anxiety and depression (click here to see the infographic at full size). The scale of both anxiety and depression is vast: the World Health Organization estimates that 301 million people worldwide suffer from an anxiety disorder, and 280 million people worldwide suffer from depression. Worldwide, depression ranks as the second largest cause of disability, and anxiety ranks eighth, according to analyses of the most recent Global Burden of Disease study. And yet, despite their prevalence and severe impacts, humanity's scientific understanding has a substantial way to go to fully understand and highly reliably treat these conditions. Improved treatment and management techniques could make a huge difference in the quality of life of hundreds of millions of people around the world. These astounding statistics have motivated us to run our own studies investigating how these conditions work and how they relate to each other. This article will explain what we found! Overlapping Disorders A major obstacle to understanding anxiety and depression is that they often go together - many people who experience one also experience the other. Approximately 45% of people who experience a depressive disorder in their lifetime also experience an anxiety disorder, and these often occur during the same timeframe. Among people with Generalized Anxiety Disorder, about 43% of them will also experience depression in their lifetime. In one of our own studies, we found that commonly used measures of anxiety and depression (the GAD7 and PHQ9 scales) had shockingly high correlations (r=0.82). These strong links between anxiety and depression can make it more difficult to disentangle how each of these disorders works and make it more difficult for a person with anxiety and depression to effectively manage their conditions. Some people even think they have an anxiety disorder when it's more accurate to say they have a depressive disorder or the reverse. The co-occurrence of anxiety and depression is a bit puzzling because they almost seem like opposites when experienced in the moment. A high level of anxiety often feels like being “wound up” - muscle tension, rapid heart rate, and chest tightness are among the most common physical symptoms. People experiencing anxiety may have a nervous energy that makes it difficult for them to relax, even if there is nothing they can practically do to address whatever is making them anxious. Depression, on the other hand, often feels like struggling to muster energy or motivation to care about things enough to take any action at all. Doing things, including things that a perso...

Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: Longlist of Causes + Cause Exploration Contest, published by Joel Tan (CEARCH) on July 1, 2023 on The Effective Altruism Forum. Longlist of Causes CEARCH keeps a running longlist of causes (link) that may merit further research to see if they are highly impactful causes worth supporting. The list, which covers the broad areas of global health & development, longtermism, as well as EA meta, is currently around 400 causes long. In compiling this longlist, we have used a variety of methods, as detailed in this search methodology (link); core ones include: Using Nuno's excellent list as a starting point. Conducting consultations and surveys (e.g. of both EA and non-EA organizations and individuals). Performing outcome tracing (i.e. looking at good/bad outcomes and identifying the underlying causes): The Global Burden of Diseases database and the World Database of Happiness are especially useful in this regard. Our hope is that this list is useful to the community, and not just our own research team. Notes: Classification of causes is fairly arbitrary, and each organization has their own approach. CEARCH find it useful to think of causes in three distinct levels, from broadest to narrowest: (1) High-level cause domain, which are problems defined in the broadest way possible: (a) global well-being, which concerns human welfare in the near-term; (b) animal welfare, which is self-explanatory; (c) longtermism, which concerns human welfare in the long-term; and (d) EA meta, which involves doing good through improving or expanding effective altruism itself. (2) Cause areas, which are significantly narrowed down from high-level cause domains, but are still fairly broad themselves. For example, within global well-being, we might have global health, economic & development, political reform etc (3) Causes, which are problems defined in a fairly narrow way (e.g. malaria, vitamin A deficiency, childhood vaccination, hypertension, diabetes etc). Of course, causes can always be broken down further (e.g. malaria in sub-Saharan Africa, or childhood vaccination for diphtheria), and going through our list, you can also see that causes may overlap (e.g. air pollution in a general sense, vs ambient/outdoor particulate matter pollution, vs indoor air quality, vs specifically indoor household air pollution from soot). The reason for such overlap is partly a lack of time on CEARCH's part to rationalize the whole list; but partly it also reflects our view that it can be valuable to look at problems at different levels of granularity (e.g. at higher levels, a single intervention may be able to solve multiple problems at the same time, such that a broader definition of a cause areas helps find more cost-effective solutions; conversely, at lower levels, you can focus on very targeted interventions that may be very cost-effective but not generally applicable). Note that animal welfare causes are not in this longlist, as CEARCH has so far not focused on them, for want of good moral weights to do evaluations with. This should not be taken to imply that animal causes are unimportant, or that research into cost-effective animal causes is not valuable. Cause Exploration Contest Open Philanthropy had its excellent Cause Exploration Prize; here, we'll like to do something similar but make the bar significantly lower. We invite people to suggest potential cause areas, providing a short justification if you feel it useful (e.g. briefly covering why the issue is important/tractable/neglected), or not, if otherwise (e.g. the idea simply appears novel or interesting to you). All ideas are welcome, and even causes which do not appear intuitively impactful can be fairly cost-effective upon deeper research. People are also welcome to suggest potential search methodologies for finding causes (e.g. consulting weird ...

We've all heard vegan diets are better for our health and the planet. But what you might not know is there are many vested interests in the “plant-based” message and vegan diets can cause serious (and sometimes irreversible) health issues, especially for kids. Which is why in this week's podcast brilliant author and journalist, Jayne Buxton, breaks down the serious flaws with plant-based diets outlined in her groundbreaking book, The Plant-Based Con. If you are considering going vegan for your health or the planet or have friends and family who are, this podcast is a must-listen!  Here are some of my favorite takeaways: Common nutrient deficiencies in vegan diets Why anti-nutrients can be an issue for vegans The dangers of vegan diets in kids Who benefits from plant-based messaging Why the media is reluctant to talk about the danger of vegan diets The problem with the research against meat Why dietary guidelines recommend reducing red meat The real dietary culprits The truth about beef's environmental footprint Why models of food's carbon emissions can be faulty Why the Global Burden of Disease's recommendation to avoid red meat is problematic Why the “eat less meat” message benefits the economy How her life has changed since she wrote the book Please listen and share this important information with anyone who may benefit. I sincerely hope it's helpful.   Valuable Resources: Paleovalley Grass Fed Beef Sticks >>> Try the highest quality, nutrient-dense, clean protein with Paleovalley's 100% Grass Fed Beef Sticks HERE! The Great Plant-Based Con - Jayne Buxton >>> Learn more about Jayne Buxton's work + Get the book HERE!

Hoy viene mi querido Alex Asz a hablarnos sobre los problemas de encías y cómo es que muchos ni en cuanta que los tienen. Según el Global Burden of Disease Study, 2019, las enfermedades bucodentales, afectan a cerca de 3,500 millones de personas en todo el mundo y muchos no tienen idea, incluso empiezan con problemas de encías y terminan con pérdidas dentales.

This week on the podcast I'm joined by friend of the podcast, Monica Reinagel.  We're discussing a recent episode of the Nutrition Diva that Monica recorded based on a listener question.  The question spurred Monica to dive into a 2022 article analyzing the 2020 Global Burden of Disease Study.  We're talking about it all (and then some).  To listen to the Nutrition Diva podcast:  Nutrition Diva Podcast Meta-Analysis 2022 Canada's Guidance on Alcohol and Health: Final Report 2023 Alcohol Truths: How Much is Safe?  Buy Breaking the Bottle Legacy: How to Change Your Drinking Habits and Create A Peaceful Relationship with Alcohol on Amazon or most online retailers.  US Kindle US Paperback UK Kindle UK Paperback Apple Books Barnes & Noble Kobo Join my private FB group Alcohol Minimalists here: https://www.facebook.com/groups/changeyouralcoholhabit Has this podcast helped you? Please leave a review wherever you listen to podcasts!  This week on the podcast I'm talking about what causes your drinking...and why alcohol isn't the problem.  Follow me on Instagram: @AlcoholMinimalist  Have you grabbed your free e-book, "Alcohol Truths: How Much is Safe?" Get it here.  Low risk drinking guidelines from the NIAAA: Healthy men under 65: No more than 4 drinks in one day and no more than 14 drinks per week. Healthy women (all ages) and healthy men 65 and older: No more than 3 drinks in one day and no more than 7 drinks per week. One drink is defined as 12 ounces of beer, 5 ounces of wine, or 1.5 ounces of 80-proof liquor. So remember that a mixed drink or full glass of wine are probably more than one drink. Abstinence from alcohol Abstinence from alcohol is the best choice for people who take medication(s) that interact with alcohol, have health conditions that could be exacerbated by alcohol (e.g. liver disease), are pregnant or may become pregnant or have had a problem with alcohol or another substance in the past. Benefits of “low-risk” drinking Following these guidelines reduces the risk of health problems such as cancer, liver disease, reduced immunity, ulcers, sleep problems, complications of existing conditions, and more. It also reduces the risk of depression, social problems, and difficulties at school or work. If you' are unsure about whether or not you have alcohol use disorder, please visit the NIAAA for more information.